Editor’s note: On September 22, 2023, a U.S. Center for Disease Control advisory board recommended that an RSV vaccine, made by Pfizer, be given between the 32nd and 36th week of pregnancy. Pregnant ...
The respiratory syncytial virus (RSV) vaccine showdown already saw a shake-up last month with a new competitor in Moderna’s mRESVIA. Now, all three vaccine offerings face a potentially shrunken market ...
Respiratory syncytial virus (RSV) can cause substantial morbidity and mortality among older adults. An mRNA-based RSV vaccine, mRNA-1345, encoding the stabilized RSV prefusion F glycoprotein, is under ...
An FDA advisory panel voted today to recommend that the Pfizer RSV vaccine be approved for pregnant individuals. A recent study finds that an experimental RSV vaccine appears to be effective in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results